These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17984734)

  • 21. [Blood pressure and type 2 diabetes mellitus: impact of the insulin therapy].
    Dakhli S; Lamine S; Lamine F; Trabelsi N; Aouididi F; Zouaoui C; Mami FB; Achour A
    Tunis Med; 2007 Nov; 85(11):945-50. PubMed ID: 19166146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current status of oral agents in diabetes.
    Kilo C
    Compr Ther; 1982 Dec; 8(12):26-32. PubMed ID: 7160161
    [No Abstract]   [Full Text] [Related]  

  • 23. Endoplasmic reticulum stress in beta cells: latent mechanism of secondary sulfonylurea failure in type 2 diabetes?
    Qian L; Zhang S; Xu L; Peng Y
    Med Hypotheses; 2008 Dec; 71(6):889-91. PubMed ID: 18786775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of sulfonylureas during pregnancy: some incidental observations.
    Zargar AH; Laway BA; Masoodi SR; Bashir MI; Bhat MH
    J Assoc Physicians India; 2004 Feb; 52():168-9. PubMed ID: 15656061
    [No Abstract]   [Full Text] [Related]  

  • 25. Follow-up of intensive glucose control in type 2 diabetes.
    Petrie JR
    N Engl J Med; 2009 Jan; 360(4):416-7; author reply 418. PubMed ID: 19172672
    [No Abstract]   [Full Text] [Related]  

  • 26. Follow-up of intensive glucose control in type 2 diabetes.
    Mühlhauser I
    N Engl J Med; 2009 Jan; 360(4):417; author reply 418. PubMed ID: 19172674
    [No Abstract]   [Full Text] [Related]  

  • 27. Factors associated with physicians' decision to discontinue or down-titrate sulfonylureas for type 2 diabetes patients.
    Laires P; Kurtyka K; Witt EA; Qiu Y; Yu S; Iglay K
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):71-79. PubMed ID: 30130985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulfonylureas.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2015 Jan; 65(1):101-4. PubMed ID: 25831689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When--and how--to use an oral agent.
    Shuman CR
    Med Times; 1980 May; 108(5):77-81, 85-6. PubMed ID: 7374409
    [No Abstract]   [Full Text] [Related]  

  • 30. The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes.
    Itakura H; Abbasi F; Lamendola C; Basina M; Reaven G
    Diabetes Obes Metab; 2008 Aug; 10(8):685-7. PubMed ID: 18476981
    [No Abstract]   [Full Text] [Related]  

  • 31. Exenatide and acute pancreatitis.
    Tripathy NR; Basha S; Jain R; Shetty S; Ramachandran A
    J Assoc Physicians India; 2008 Dec; 56():987-8. PubMed ID: 19322980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic effect of augmentation strategies in patients with type 2 diabetes initiated on sulfonylureas.
    Kalsekar I; Latran M
    Manag Care Interface; 2007 Sep; 20(9):39-46. PubMed ID: 18161391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma concentration of pioglitazone in patients with type 2 diabetes on hemodialysis.
    Abe M; Kikuchi F; Okada K; Matsumoto K
    Ther Apher Dial; 2009 Jun; 13(3):238-9. PubMed ID: 19527473
    [No Abstract]   [Full Text] [Related]  

  • 34. Type 2 diabetes: which drug as add-on to metformin?
    Madsbad S
    Lancet; 2012 Jun; 379(9833):2222-3. PubMed ID: 22683136
    [No Abstract]   [Full Text] [Related]  

  • 35. Insulin requirement after one year of insulin therapy in type 2 diabetic patients dependent on fasting C-peptide.
    Biesenbach G; Bodlaj G; Pieringer H; Raml A
    Neth J Med; 2008 Jun; 66(6):259-60. PubMed ID: 18689911
    [No Abstract]   [Full Text] [Related]  

  • 36. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
    Holstein A; Hahn M; Stumvoll M; Kovacs P
    Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral hypoglycemic agents and heart.
    Manoria P; Manoria P
    Indian Heart J; 2007; 59(3):266-72. PubMed ID: 19124937
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A; Borot S; Raccah D
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral therapeutic system delivering a water insoluble drug: N-(4-[2-(3-methylpyrazole-1-carbonamide)ethyl]-benzenesulfonyl)N - cyclohexylurea (SPC-5002).
    Janicki S; Jedras Z; Sawicki W
    Acta Pharm Hung; 1988 Jul; 58(4):145-51. PubMed ID: 3223284
    [No Abstract]   [Full Text] [Related]  

  • 40. A 48-year-old man with uncontrolled diabetes.
    Hu M; Isaacson JH
    Cleve Clin J Med; 2009 Jul; 76(7):413-6. PubMed ID: 19570974
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.